Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Shah, Nirav N., Ahn, Kwang Woo, Litovich, Carlos, Fenske, Timothy S., Ahmed, Sairah, Battiwalla, Minoo, Bejanyan, Nelli, Dahi, Parastoo B., Bolaños-Meade, Javier, Chen, Andy I., Ciurea, Stefan O., Bachanova, Veronika, DeFilipp, Zachariah, Epperla, Narendranath, Farhadfar, Nosha, Herrera, Alex F., Haverkos, Bradley M., Holmberg, Leona, Hossain, Nasheed M., Kharfan-Dabaja, Mohamed A., Kenkre, Vaishalee P., Lazarus, Hillard M., Murthy, Hemant S., Nishihori, Taiga, Rezvani, Andrew R., D’Souza, Anita, Savani, Bipin N., Ulrickson, Matthew L., Waller, Edmund K., Sureda, Anna, Smith, Sonali M., Hamadani, Mehdi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2018
Gaiak:
Transplantation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916010/
https://ncbi.nlm.nih.gov/pubmed/29685953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018018531
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak